Browse by content type
Our read on the CY2027 Medicare Physician Fee Schedule proposed rule
The proposed rule tightens the screws on fee-for-service remote monitoring in the same season CMS opens an outcomes-paid lane beside it. Read together, the two moves point in one direction: away from billing for monitoring, toward being paid for prevention.
Jul 2026AnalysisWhat the CMS ACCESS Model means for outcome-based care
Outcome-aligned payment changes the question a provider's data has to answer — from "did we deliver the service?" to "can we prove the result?" That is a harder question, and most monitoring data cannot yet answer it.
Jul 2026PerspectiveThe case for continuous over periodic monitoring in value-based care
This is an argument we are working to prove, not a settled claim. The honest state of the evidence is that continuous monitoring has beaten periodic in exactly one domain. Whether it generalizes is the question, and value-based care is where it will be answered.
Jul 2026PerspectiveThe governance line between wellness and clinical AI
The line between a wellness product and a regulated medical device is real, it is enforced, and as the past year proved, it moves. That is exactly why it cannot be hard-coded into a product. It has to be a policy the product enforces and can change.
Jul 2026PerspectiveWhy neutral infrastructure keeps getting acquired
A neutral data layer is worth most to the party that would end its neutrality. That is the pattern's engine, and it explains both why these layers keep getting bought and what is lost each time one is.
Jul 2026PodcastBuilding the Clinical Compliance Layer
On Paradigm Shock, AnyBio CEO Stephen Saine sat down with host Anjon Roy to talk through the real obstacle to AI in clinical care: not the intelligence, but whether a hospital can trust it near a patient.
May 2026FilingThe FDA RFI comment on AI in early-phase trials
Our public position on continuous device endpoints in next-generation trials, filed with the FDA.
2026The bottleneck isn't intelligence anymore. It's the trusted path to the patient.
In healthcare, the hard part is no longer the intelligence. Models, algorithms, and devices keep getting better. The hard part is the trusted path to the patient: the neutral, governed layer that lets any validated device, algorithm, or model reach real clinical care with provenance, audit, and compliance intact. AnyBio is that layer. You stay a device, IP, or care company; we are the compliant processor of record, the regulated path into care. The model keeps improving; the governed path it runs on is the part that lasts.
Talk through where this is going.
We'll walk through your program and where the regulatory and market shifts leave it.
